The news is directly related to Halozyme Therapeutics. The lowering of the price target might indicate a slightly less optimistic outlook for the company's stock, but the maintained 'Buy' rating suggests that the analyst still sees potential for the stock's growth. This could lead to mixed reactions in the market, hence the neutral score.